Here are four notes:
1. Rep. Brady said he will not back Mr. Trump’s plan to allow Medicare to negotiate prices for pharmaceuticals.
2. The proposal to allow Medicare to negotiate drug prices has long been a part of Democratic healthcare platforms.
3. Rep. Brady said that allowing this proposal would limit access since drugs that are more expensive, but also more effective, may be rejected.
4. Rep. Brady also said studies have shown the proposal would not save money.
More articles on ASC coding & billing:
6 steps for ASCs to gain surgeon support in implant price negotiations
Million-dollar losses & thousands of uninsured: Will the remaining 7 co-ops persevere or fall prey to the turbulent payer marketplace?
Payer mega-mergers on the fritz: Justice Department could file blocking suit — 5 highlights
